Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Oren

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Journal of the Neurological Sciences|July 11, 2006
Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptomsL Elmer, S Schwid, S Eberly, et al.
Nucleic Acid Therapeutics|August 29, 2023
Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis PatientsEfrat Ozeri-Galai, Lital Friedman, Ofra Barchad-Avitzur, et al.
Cell Stem Cell|January 16, 2013
Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screenUri Ben-David, Qing-Fen Gan, Tamar Golan-Lev, et al.
EMBO Molecular Medicine|April 8, 2014
The unfolded protein response affects readthrough of premature termination codonsYifat S Oren, Michelle L McClure, Steven M Rowe, et al.
Annals of the Rheumatic Diseases|November 6, 2007
Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral responseS Oren, M Mandelboim, Y Braun-Moscovici, et al.
Plos One|March 26, 2013
LRRC6 mutation causes primary ciliary dyskinesia with dynein arm defectsAmjad Horani, Thomas W Ferkol, David Shoseyov, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 1, 2022
Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutationYifat S Oren, Ofra Avizur-Barchad, Efrat Ozeri-Galai, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 25, 2026
SPL84 and trikafta® exhibit comparable and additive effects in patient-derived HBE cells carrying the 3849+10kb C→T/F508del CFTR variantsYi Cheng, Yifat S Oren, Jan Harrington, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 6, 2021
Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutationYifat S Oren, Michal Irony-Tur Sinai, Anita Golec, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Journal of the Neurological Sciences|July 11, 2006
Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptomsL Elmer, S Schwid, S Eberly, et al.
Nucleic Acid Therapeutics|August 29, 2023
Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis PatientsEfrat Ozeri-Galai, Lital Friedman, Ofra Barchad-Avitzur, et al.
Cell Stem Cell|January 16, 2013
Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screenUri Ben-David, Qing-Fen Gan, Tamar Golan-Lev, et al.
EMBO Molecular Medicine|April 8, 2014
The unfolded protein response affects readthrough of premature termination codonsYifat S Oren, Michelle L McClure, Steven M Rowe, et al.
Annals of the Rheumatic Diseases|November 6, 2007
Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral responseS Oren, M Mandelboim, Y Braun-Moscovici, et al.
Plos One|March 26, 2013
LRRC6 mutation causes primary ciliary dyskinesia with dynein arm defectsAmjad Horani, Thomas W Ferkol, David Shoseyov, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 1, 2022
Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutationYifat S Oren, Ofra Avizur-Barchad, Efrat Ozeri-Galai, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 25, 2026
SPL84 and trikafta® exhibit comparable and additive effects in patient-derived HBE cells carrying the 3849+10kb C→T/F508del CFTR variantsYi Cheng, Yifat S Oren, Jan Harrington, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 6, 2021
Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutationYifat S Oren, Michal Irony-Tur Sinai, Anita Golec, et al.
Pageof 8